Trial Code
Ages
Location
Gender
Ethnicity
Payment
Nicotine Restrictions
Are you living with Von Willebrand Disease?
Your daily experience matters. Help us understand VWD better, and help researchers develop potential treatments to prevent bleeding.
What we want to learn from you:
- Your daily reality - how does VWD affect your work, relationships and daily activities?
- Your bleeding patterns - when bleeds occur, how severe they are and what triggers them?
- Your treatment use - what treatments do you use for your bleeds?
What is the study?
- We are conducting a study for people with von Willebrand Disease (VWD).
- In this study we are recruiting male and female participants aged between 16 and 69 years old.
- We will conduct several clinical assessments to collect information regarding bleeding events, quality of life, and the social and clinical impact of bleeding events.
- You will be paid for your time and commitment if you participate in this study.
Who can take part?
We will check your suitability for the clinical trial using the following criteria: -
- You must be aged between 16 and 69 years old.
- You must weigh 45 to 132 kg at Screening and have a body mass index less than 38.5 kg/m2.
- You must have been diagnosed with von Willebrand Disease (VWD).
- You must not have any severe bleeding disorder other than VWD or a family history of clotting events.
Where does the study take place?
After an initial visit to Richmond Pharmacology’s clinic near London Bridge, you will be recording entries in an electronic diary from your own home, in your own time, with only a couple more visits to the clinic required. We are happy to arrange and pay for your transportation to and from our London clinic.
Payment
In recognition of the time involved in taking part in the study, you will receive £2,036 if you are 18 years old when you complete 48 weeks of the study; if you are under 18 years old you will be given £2,036 in vouchers of your choice on completion of 48 weeks, provided you comply fully with all the clinical trial requirements. This amount is based on the anticipated clinical trial plan and will be adjusted pro-rata (i.e. same amount of money paid per unit of time), should we invite you to attend extra visits.
Approval
The contents of this email have been approved by an ethics committee. Any response to this advertisement will be recorded. Your response will not place you under any obligation to participate in this trial.
You may be required to remain resident in the unit until resolution of any safety issues, after which you will be discharged from the unit.
Ref: C23024_Apr_2026 (email_website_advert text)
